Axsome Therapeutics Director Susan Mahony's Stock Transactions

Axsome Therapeutics, Inc. director Susan Mahony reported several stock transactions in a Form 4 filing. On June 8, 2026, 1,429 restricted stock units (RSUs) granted on June 6, 2025, vested and converted to common stock at $0 per share, increasing her holdings to 1,429 shares. The RSUs were part of a one-year vesting schedule. Subsequently, on June 9 and June 10, 2026, Mahony sold 300 shares each day at $237.21 and $246.18 per share respectively through a pre-approved 10b5-1 trading plan. These sales were executed to cover tax obligations related to the RSU settlement. Following these transactions, her total direct holdings decreased to 829 shares. The transactions were completed through an attorney-in-fact, Nick Pizzie.